Testing human biologicals in animal host resistance models

Journal of Immunotoxicology

Volumn 5, Issue 1, 2008, Pages 23-31

  Burleson, Gary R ^a   Burleson, Florence G ^a  

^a BRT Burleson Research Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; DEXAMETHASONE; ENVIRONMENTAL CHEMICAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NATALIZUMAB; POLYSACCHARIDE; RECEPTOR; RITUXIMAB; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CANDIDA ALBICANS; CELLULAR IMMUNITY; CONFERENCE PAPER; CROHN DISEASE; CYTOMEGALOVIRUS; EVALUATION; GENETIC ENGINEERING; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTOXICITY; INFECTION; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MACROPHAGE; MEDIATOR; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSEUDOMONAS AERUGINOSA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; T LYMPHOBLAST;

ANIMALS; BIOLOGICAL PRODUCTS; BIOMARKERS, PHARMACOLOGICAL; COMMUNICABLE DISEASES; DISEASE SUSCEPTIBILITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNITY, INNATE; MICE; MODELS, ANIMAL; RATS; RISK ADJUSTMENT;

ANIMALIA; BACTERIA (MICROORGANISMS); CANDIDA ALBICANS; LISTERIA MONOCYTOGENES; MURID HERPESVIRUS 1; MUS; ORTHOMYXOVIRIDAE; PSEUDOMONAS AERUGINOSA; RODENTIA; STREPTOCOCCUS PNEUMONIAE;

EID: 41149131734     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910801897557     Document Type: Conference Paper

References (53)

1. Alford, C. A., and Britt, W. J. 1990. Cytomegalovirus. In: Virology, Second Edition (Fields, B. N., Knipe, D. M., Chanock, R. M., Hirsch, M S., Melnick, J. L., Monath, T. P., and Roizman, B., Eds.), New York: Raven Press, Ltd., pp. 1981-2010.
2. Arbeit, J. M., and Hirose, R. 1999. Murine mentors: Transgenic and knockout models of surgical disease. Ann. Surg. 229:21-40.
3. Benton, K. A., VanCott, J. L., and Briles, D. E. 1998. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect. Immun. 66:839-842.
4. Bradley, S. G. 1995. Chapter 13. Listeria Host Resistance Model. In: Methods in Immunotoxicology, Volume 2 (Burleson, G. R., Dean, J. H., and Munson, A. E., Eds.), New York: Wiley-Liss, Inc., pp. 169-179.
5. Burleson, G. R. 1995. Chapter 14. Influenza virus host resistance model for assessment of immunotoxicity, immunostimulation, and antiviral compounds. In: Methods in Immunotoxicology, Volume 2 (Burleson, G. R., Dean, J. H., and Munson, A. E., Eds.), New York: Wiley-Liss, Inc., pp. 181-202.
6. Burleson, G. R. 1996. Chapter 7. Pulmonary immunocompetence and pulmonary immunotoxicology. In: Experimental Immunotoxicology (Smialowicz, R., and Holsapple, M. P., Eds.), Boca Raton, FL: CRC Press, Inc., pp. 113-135.
7. Burleson, G. R. 2000. Models of respiratory immunotoxicology and host resistance. Immunopharmacology 48:315-318.
8. Burleson, G. R., and Burleson, F. G. 2007. Influenza virus host resistance model. Methods 41:31-37.
9. Burleson, G. R., and Dean, J. H. 1995. Chapter 1. Immunotoxicology: Past, present, and future. In: Methods in Immunotoxicology, Volume 1, (Burleson, G. R., Dean, J. H., and Munson, A. E., Eds.), New York: Wiley-Liss, Inc., pp. 3-10.
10. Burleson, G. R., and Burleson, F. G. 2007. Host resistance models to evaluate immunotoxicity. In: Immunotoxicology Strategies for Pharmaceutical Safety Assessment. (Herzyk, D., and J. Bussiere, J., Eds.), New York: John Wiley & Sons, Inc. (In Press).
11. Burleson, G. R., Ibanes, J. D., and Morgan, K. T. 1995. Immunology and immunotoxicity of the respiratory tract. Fundam. Appl. Toxicol. 26:11-19.
12. Centers for Disease Control and Prevention. 1997. Pneumococcal polysaccharide Vaccine. What You Need to Know. July, 1997.
13. Conlan, J. W., and North, R. J. 1991. Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium. J. Exp. Med. 174:741-744.
14. Conlan, J. W., and North, R. J. 1992. Monoclonal antibody NIMP-R10 directed against the CD11b chain of the type 3 complement receptor can substitute for monoclonal antibody 5C6 to exacerbate listeriosis by preventing the focusing of myelomonocytic cells at infectious foci in the liver. J. Leukocyte Biol. 52:130-132.
15. Cowan, L. A., Burleson, G. R., Burleson, F. G., and Bussiere, J .L. 2002. The response of C57BL/6 mice to the mouse influenza host resistance (MIHR) model. The Toxicologist 66:238.
16. Eckhart, W. 1990. Chapter 56. Polyomavirinae and their replication. In: Virology, Second Edition (Fields, B. N., Knipe, D. M., Chanock, R. M., Hirsch, M S., Melnick, J. L., Monath, T. P., and Roizman, B., Eds.), New York: Raven Press, Ltd., pp. 1593-1607.
17. Fox, R. I. 2007. FDA alert for Rituximab in patients with systemic lupus erythematosus. Medscape Rheumatology.
18. Garssen, J., van der Vliet, H., De Klerk, A., Goettsch, W., Dormans, J. A., Bruggeman, C. A., Osterhaus, A. D., and Van Loveren, H. 1995. A rat cytomegalovirus infection model as a tool for immunotoxicity testing. Eur. J. Pharmacol. 292:223-231.
19. 3 exposure: Differences in disease susceptibility and neutrophil recruitment. Toxicol. Appl. Pharmacol. 123:211-218.
20. Gilmour, M. I., Park, P., and Selgrade, M. K. 1993. Ozone-enhanced pulmonary infection with Streptococcus zooepidemicus in mice. Am. Rev. Respir. Dis. 147:753-760.
21. Gleichmann, E., I. Kimber, I., and Purchase, I. F. H. 1989. Immunotoxicology: Suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. Arch. Toxicol. 63:257-273.
22. Goettsch, W., Garssen, J., de Gruijl, F. R., and Van Loveren, H. 1994. Effects of UV-B on the resistance against infectious diseases. Toxicology 72:359-363.
23. Gosselin, D., DeSanctis, J., Boule, M., Skamene, E., Matouk, C., and Radzioch, D. 1995. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect. Immun. 63:3272-3278.
24. Ibanes, J. D., Morgan, K. T., and Burleson, G. R. 1996. Histopathological changes in the upper respiratory tract of F344 rats following infection with a rat adapted influenza virus. Vet. Pathol. 33:412-418.
25. Jonjić, S., Pavić, I., Polić, B., Crnković, I., Lučin, P., and Koszinowski, U. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179:1713-1717.
26. Jordan, M. C., Shanley, J. D., and Stevens, J. G. 1977. Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J. Gen. Virol. 37:419-423.
27. Leung, K. N., and Ada, G. L. 1981 Effect of helper cells on the primary in vitro production of delayed-type hypersensitivity to influenza virus. J. Exp. Med. 153:1029-1043.
28. Leung, K. N., Ashman, R. B., Ertl, H. C. J., and Ada, G. L. 1980. Selective suppression of the cytotoxic T cell response to influenza infection in mice. Eur. J. Immunol. 10:803-810.
29. Miller, R. E., Branstetter, D., Armstrong, A., Kennedy, B., Jones, J., Cowan, L., Bussiere, J., and Dougall, W. C. 2007. Receptor activator of NF-κB Ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J. Immunol. 179:266-274.
30. Mohan, V. P., Scanga, C. A. , Keming, Y., Scott, H. M., Tanaka, K. R., Tsang, E., Tsai, M. C., Flynn, J. L., and Chan, J. 2001. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role of limiting pathology. Infect. Immun. 69:1847-1855.
31. O'Brien, D. P., Briles, D. E., Szalai, A. J., Tu, A. H., Sanz, I., and Nahm, M. H. 1999. Tumor necrosis factor alpha I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 67:595-601.
32. Olivier, K. J., Palmer, V., Burleson, F., Burleson, G., Morrow, J., Taylor, F., and Clark, J. B. 2007. Inhibition of the murine α1β1 integrin does not affect the primary immune response to influenza virus in Balb/c mice. The Toxicologist 96:360.
33. Polić, B., Hengel, H., Krmpotić, A., Trgovcich, J., Pavić, I., Lučin, P., Jonjić, S., and Koszinowski, U. 1998. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188:1047-1054.
34. Roque, R., Ponce, R., Burleson, F., Cabrit, M., Broly, H., and Rogge, M. 2006. Influenza virus host response of C57BL/6 mice treated with TACI-Ig. Immunopharm. Immunotoxicol. 28:13-32.
35. Rosen, H., Gordon, S., and North, R. J. 1989. Exacerbation of murine listeriosis by a monoclonal antibody specific for the type 3 complement receptor of myelomonocytic cells. Absence of monocytes at infective foci allows Listeria to multiply in non-phagocytic cells. J. Exp. Med. 170:27-37.
36. Ross, P. S., de Swart, R. L., van der Vliet, H., Willemsen, L., De Klerk, A., Van Amerongen, G., Groen, J., Brouwer, A., Schipholt, I., Morse, D. C., and van Loveren, H. 1997. Impaired cellular immune response in rats exposed perinatally to Baltic Sea herring oil or 2,3,7,8-TCDD. Arch. Toxicol. 71:563-574.
37. Ross, P. S., van Loveren, H., de Swart, R. L., van der Vliet, H., de Klerk, A., Timmerman, H. H., Van Binnendijk, R., Brouwer, A., Vos, J. G., and Osterhaus, A. D. 1996. Host resistance to rat cytomegalovirus (RCMV) and immune function in adult PVG rats fed herring from the contaminated Baltic Sea. Arch. Toxicol. 70:661-671.
38. Selgrade, M. J. K., and Daniels, M .J. 1995. Chapter 15. Host resistance models: Murine cytomegalovirus. In: Methods in Immunotoxicology, Volume 2, (Burleson, G. R., Dean, J. H., and Munson, A. E., Eds.), New York: Wiley-Liss, Inc., pp. 203-219.
39. Selgrade, M. J. K., Daniels, M .J., Burleson, G. R., Lauer, L. D., and Dean, J. H. 1988. Effects of 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene, and cyclosporine A on murine cytomega-lovirus infection: Studies of resistance mechanisms. Int. J. Immunopharmacol. 10:811-818.
40. Shanley, J. D., Jordan, M. C., Cook, M. L., and Stevens, J. G. 1979. Pathogenesis of reactivated latent murine cytomegalovirus infection. Am. J. Pathol. 95:67-80.
41. Shulstz, L. D., Ishikawa, F., and Greiner, D. L. 2007. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7:118-130.
42. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76:301-314.
43. Steele, T. D., Geng, W., Burleson, F., and Burleson, G. 2005. Enfuvirtide does not impair host resistance to infection in rats. The Toxicologist 84:178.
44. Takashima, K., Tateda, K., Matsumoto, T., Iizawa, Y., Nakao, M., and Yamaguchi, K. 1997. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65:257-260.
45. Van der Poll, T., Keogh, C. V., Buurman, W. A., and Lowry, S. F. 1997. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice. Am. J. Crit. Care Med. 155:603-608.
46. Van Loveren, H. 1995. Host resistance models. Human Exp. Toxicol. 14:137-140.
47. Wellmer, A., Gerber, J., Ragheb, J., Zysk, G., Kunst, T., Smirnov, A., Brück, W., and Nau, R. 2001. Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect. Immun. 69:6881-6886.
48. Whitley, R. J. 1990. Chapter 66. Herpes Simplex Viruses. In: Virology, 2nd Edition (Fields, B. N., Knipe, D. M., Chanock, R. M., Hirsch, M. S., Melnick, J. L., Monath, T. P., and Roizman, B., Eds.), New York: Raven Press, Ltd., pp. 1843-1887.
49. Yap, K. L., and Ada, G. L. 1978. Transfer of specific cytotoxic T-lymphocytes protects mice inoculated with influenza virus. Nature 273:238-239.
50. Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jager, H. R., and Clifford, D. B. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl. J. Med. 354:924-933.
51. Yucesoy, B., Vallyathan, V., Landsittel, D. P., Sharp, D. S., Matheson, J., Burleson, F., and Luster, M. 2001a. Polymorphisms in the IL-1 gene complex in coal miners with silicosis. Am. J. Ind. Med. 39:286-291.
52. Yucesoy, B., Vallyathan, V., Landsittel, D. P., Sharp, D. S., Weston, A., Burleson, G. R., Simeonova, P., McKinstry, M., and Luster, M. I. 2001b. Association of TNFα and IL-1 gene polymorphisms with silicosis. Toxicol. Appl. Pharmacol. 172:75-82.
53. Zhu, Y., Herlaar, E., Masuda, E. S., Burleson, G. R., Nelson, A. J., Grossbard, E. B., and Clemens, G. R. 2007. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol. Appl. Pharmacol. 221:268-277.